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Abstract: Numerous studies have demonstrated that cardiac bio-
markers are significant predictors of cardiovascular (CV) and all-cause
mortality in ESRD patients, but most of the studies were retrospective or
included small numbers of patients, only prevalent dialysis patients, or
measured 1 or 2 biomarkers. This study was to analyze the association
between 3 cardiac biomarkers and mortality in incident HD patients. A
prospective cohort of 864 incident HD patients was followed for 30
months. Based on the median values of baseline NT-proBNP, cTnT, and
hsCRP, the patients were divided into ‘‘high’’ and ‘‘low’’ groups, andCV
and all-causemortalitywere compared between each group.Additionally,
time-dependent ROC curveswere constructed, and theNRI and IDI of the
models with various biomarkers were calculated. The CV survival rates
were significantly lower in the ‘‘high’’ NT-proBNP and cTnT groups
compared to the corresponding ‘‘low’’ groups, while there was no
significant difference in CV survival rate between the 2 hsCRP groups.
However, all-cause mortality rates were significantly higher in all 3
‘‘high’’ groups compared to each lower group. In multivariate analyses,
only Ln NT-proBNP was found to be an independent predictor of
mortality. Moreover, NT-proBNP was a more prognostic marker for
mortality compared to cTnT. In conclusion, NT-proBNP is the biomarker
that results in the most added prognostic value on top of traditional riskD, PhD, Nam-H hD,
ng, MD, PhD
Abbreviations: CAD = coronary arterial disease, cTnT = cardiac
troponin T, CVD = cardiovascular disease, ECG =
electrocardiogram, ESD = estimated difference, ESRD = end-
stage renal disease, HD = hemodialysis, hsCRP = high-sensitivity
C-reactive protein, iAUC = integrated area under the curve, IDI =
integrated discrimination improvement, LAD = left atrial
dimension, LVEF = left ventricular ejection fraction, LVH = left
ventricular hypertrophy, LVMI = left ventricular mass index, NRI =natriuretic peptide, PAD = peripheral arterial disease, ROC =
receiver operating characteristic.
INTRODUCTION
C ardiovascular disease (CVD) is prevalent, and is the lead-ing cause of morbidity and mortality in patients with end-
stage renal disease (ESRD).1 Among various CVDs, left ven-
tricular hypertrophy (LVH) is the most frequent CV manifes-
tation,2,3 present in more than 70% of incident ESRD patients,
and it has been shown to increase the risk for cardiac ischemia,
LV dysfunction, and sudden cardiac death.4,5 However, many
dialysis patients are asymptomatic.6 Therefore, the identifi-
cation of ESRD patients at high risk of CVD is important in
order to expedite aggressive treatment and to improve patient
outcomes.
Traditional risk factors for CVD, such as advanced age,
hypertension, diabetes, and dyslipidemia, frequently coexist in
ESRD patients,7 but they cannot fully account for the high
prevalence of CVD in these patients; therefore, research must be
performed to create better and easier tools for CVD risk
stratification in this population.8 Recently, several biochemical
markers, such as B-type natriuretic peptide (BNP), N-terminal
proBNP (NT-proBNP), cardiac troponin T (cTnT), and I (cTnI),
and high-sensitivity C-reactive protein (hsCRP), have received
attention from researchers as potential candidates to assist with
risk stratification.8–14
BNP belongs to a family of vasopeptide hormones and is
secreted in prohormone form (proBNP) from the LV in response
to wall stretch of the ventricles.15–17 In the circulation, proBNP
is cleaved into the active C-terminal fragment and the biologi-
cally inactive NT-proBNP.17 The increase in BNP and NT-
proBNP concentrations is associated with abnormal LV struc-
ture and function.18,19 Meanwhile, cTnT and cTnI are com-
ponents of the contractile apparatus of the heart muscle and are
released into the circulation after myocardial necrosis.8,20,21 In
addition, accumulating evidence has shown that myocardialked with elevated levels of cTnT and
s of cardiac biomarkers have significant
and all-cause mortality not only in the
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general population but also in patients with specific diseases,
including ESRD.8,10,11,22,23
Uremia-related nontraditional risk factors, including
inflammation and oxidative stress, have been implicated in
the pathogenesis of CVD in dialysis patients.24–27 Accordingly,
a number of previous studies investigated the association of
hsCRP, which is thought to be a biomarker for inflammation,
with the clinical outcomes in patients with ESRD and found that
there was a correlation between hsCRP levels and mortality in
these patients.11,14,27,28
Even though numerous previous studies have revealed that
cardiac and inflammatory biomarkers are significant predictors
of CV and all-cause mortality in ESRD patients, the majority
were retrospective or included small numbers of patients, only
examined prevalent dialysis patients, studied ESRD patients
with different ethnicities or dialysis modalities, or only
measured 1 or 2 biomarkers.9–11,23 In the present study, there-
fore, we compared the prognostic power of NT-proBNP, cTnT,
and hsCRP for CV and all-cause mortality in incident Korean
hemodialysis (HD) patients from the Clinical Research Center
for ESRD (CRC for ESRD) cohort. Moreover, the relationship
between these biomarkers and echocardiographic parameters
were elucidated.
SUBJECTS AND METHODS
Patients
All ESRD patients who started HD between August 1,
2009 and February 29, 2012 at 36 centers of the CRC for ESRD
in Korea were initially recruited for this prospective observa-
tional multicenter study. We excluded patients who were
younger than 18 years old, had histories of peritoneal dialysis
or kidney transplantation before HD, had underlying active
malignancy, or were expected to survive less than 3 months.
Patients who died within 3 months after the commencement of
HD were also excluded from the study. Finally, a total of 864
incident HD patients were included in the final analysis.
The study protocol was approved by the Institutional
Review Boards of each participating center and all patients
provided their written informed consent to participate in the
study.
Data Collection
Demographic and clinical data at the time of study entry,
including age, gender, body mass index (BMI) calculated as
weight/height,2 primary renal disease, comorbidities, and medi-
cations, were recorded. Coronary arterial disease (CAD) was
defined as a history of angioplasty, coronary artery bypass
grafts, myocardial infarction, or angina, while peripheral arter-
ial disease (PAD) was defined as a history of claudication,
ischemic limb loss, and/or ulceration, or peripheral revasculari-
zation. The following laboratory data were measured from
predialysis fasting blood samples taken on the day of the
midweek dialysis session close to the time of discharge, when
the patients were considered to be clinically stable and in a
euvolemic state: hemoglobin (Hb), white blood cell (WBC)
count, blood urea nitrogen, creatinine, calcium, phosphorus,
intact parathyroid hormone (iPTH), albumin, total cholesterol,
triglycerides, sodium, potassium, bicarbonate, serum iron,
ferritin, NT-proBNP, cTnT, and hsCRP. Since measurement
Oh et alof cTnI was not standardized or available in some centers of the
CRC for ESRD, cTnT was used as a marker for cardiac
troponin.
2 | www.md-journal.comNT-proBNP and cTnT concentrations were determined
using the Elecsys proBNP electrochemiluminescence immu-
noassay (Roche Diagnostics, Indianapolis, IN) and a third-
generation electrochemiluminescence immunoassay (Elecsys
Troponin T STAT Immunoassay, Roche Diagnostics), respect-
ively, while hsCRP levels were measured by a latex-enhanced
immunonephelometric method using a BNII analyzer (Dade
Behring, Newark, DE).
Echocardiography and Electrocardiogram
Echocardiography was performed on a non-dialysis day
close to the time of discharge based on the imaging protocol
recommended by the American Society of Echocardiography,29
to assess the volume status and/or cardiac function of the
patients. Even though the timing for echocardiography was
not standardized, it was mainly performed on the day after the
last or 2nd last HD performed during admission. Left atrial
dimension (LAD) was assessed at end-ventricular systole at the
level of aortic valve according to the leading-edge-to-leading-
edge convention. Left ventricular mass (LVM) was determined
using the method described by Devereux et al30 and the LV
mass index (LVMI) was calculated by dividing LVM by body
surface area. LV systolic function was defined by LV ejection
fraction (LVEF) using a modified biplane Simpson’s method
from the apical 2-chamber and 4-chamber views. We chose and
measured right ventricular systolic pressure (RVSP) to evaluate
the volume status of our patients. RVSP was measured by
continuous wave Doppler echocardiography using the modified
Bernoulli equation ( p¼ 4 v2þ right atrial pressure, where
v¼ the peak tricuspid regurgitant velocity and right atrial
pressure was assumed to be 10mm Hg). Multiple reproduci-
bility, inter-reader reliability, intrareader reliability, and reader
drift analyses were performed at a core echocardiography
laboratory (Kyungpook National University) on a 3% random
sample of the entire cohort each year. The intraclass correlation
coefficients for the echocardiographic measures were 0.773 for
LAD, 0.745 for LVMI, 0.842 for LVEF, and 0.787 for RVSP.
Furthermore, products of QRS duration multiplied by the
Cornell voltage combination (with 6mm added in
women)2440mmms were used to determine LVH on elec-
trocardiogram (ECG).31
Outcome Measures
For the current study, all mortality events were retrieved
from the database and carefully reviewed. The primary and
secondary endpoints were CV and all-cause mortality, respect-
ively. CV mortality was considered death from myocardial
infarction or ischemia, congestive heart failure, pulmonary
edema, and cerebral hemorrhage or vascular disorder.
Statistical Analysis
Statistical analyses were performed using SPSS for
Windows, version 18.0 (SPSS Inc., Chicago, IL). Continuous
variables were expressed as mean standard deviation and
categorical variables as a number (percentage). Patients were
dichotomized into ‘‘high’’ and ‘‘low’’ groups based on the
median values of NT-proBNP, cTnT, and hsCRP, and the base-
line characteristics were compared between the 2 groups using
Student’s t-test for continuous variables and the chi-square test
for categorical variables. Because the distributions of NT-
Medicine  Volume 93, Number 27, December 2014proBNP, cTnT, and hsCRP concentrations were log-normal,
natural log values (Ln) were used in the analysis. Cumulative
survival curves were generated by the Kaplan–Meier method,
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and between-group survival was compared by a log-rank test. In
addition, multivariate regression analyses with traditional risk
factors and each cardiac biomarker were conducted, and the
discrimination power of each multivariate model was compared
to assess the additional impact of each biomarker to traditional
risk factors. For a null model, we applied backward method
(specifies the significance level for entering effects¼ 0.05 and
removing effects¼ 0.05) on a candidate list of traditional risk
factors, including age, gender, hypertension, diabetes mellitus
(DM), Charlson comorbidity index (CCI), mean arterial pressure
(MAP), 24-hour urine output, hemoglobin (Hb), and serum
albumin and total cholesterol, and found that only age was a
significant variable for CV and/or all-cause mortality. Therefore,
it was inevitable to choose age, gender, hypertension, and DM,
well-known traditional risk factors of CVD, as variables of a null
model. Meanwhile, since CCI had a strong association with age
(g¼ 0.614, P< 0.001), only age was entered into the model to
avoid multicollinearity. Moreover, time-dependent receiver
operating characteristic (ROC) curve was constructed to assess
which cardiac biomarkers added the higher prognostic value.32,33
We especially compared the global concordance probability
(integrated area under the curve, iAUC) between traditional risk
factors and each cardiac biomarker by using The R Statistical
package ver. 3.0.1 (www.R-project.org). Furthermore, we calcu-
lated the net reclassification index (NRI) and the integrated
discrimination improvement (IDI) to assess the ability of the
models with biomarkers to correctly reclassify patients compared
to themodelwithout biomarkers (model including traditional risk
factors and each cardiac biomarker). The NRI required the
definition of risk strata. We defined 3 risk strata for CV and
all-causemortality based on 3 points (<33.3%, 33.3–66.6%, and
>66.6%). In the NRI, only the changes in predicted probabilities
that imply a change from 1 category to another were considered.
Therefore, the NRI expressed the global net improvement in
reclassification with the new model. By contrast, the IDI did not
require a prior definition of risk strata, thus considering the
change in the predicted probabilities as a continuous variable.34
P-values less than 0.05 were considered statistically significant.
RESULTS
Patient Characteristics
The baseline patient characteristics are shown in Table 1.
The mean age was 59.7 14.4 years old, and 513 patients
(59.4%) were male. The most common comorbid disease was
DM (56.3%), followed by hypertension (48.0%). The median
value of NT-proBNP, cTnT, and hsCRP were 6019.5 pg/mL,
0.05 ng/mL, and 0.34mg/dL, respectively. The mean values of
LAD, LVMI, LVEF, and RVSP were 4.2 cm, 185.4 g/m2,
58.5%, and 33.8mm Hg, respectively. In addition, LVH on
ECG was present in 264 patients (30.6%). The mean duration of
follow-up by a nephrologist before commencing dialysis was
10.2 months. Most patients were prescribed with low flux at the
time of HD initiation. However, 2.5% and 2.0% of this study
subjects used high flux and hemodiafiltration at the start time of
HD. Dialysis mode was changed in 152 patients (17.6%) during
study period, and most of the change was from low flux to high
flux (131/152 [86.2%] episodes). Six hundred and thirteen
patients (71.0%) used temporary catheter, and native vascular
access was available in only 206 patients (23.8%). Acute HD
Medicine  Volume 93, Number 27, December 2014was required in 485 patients (56.1%).
First, the baseline patient characteristics were compared
between the 2 dichotomized groups based on the median
# 2014 Lippincott Williams & Wilkinsconcentrations of NT-proBNP, cTnT, and hsCRP. DM and
hypertension were significantly more prevalent in the ‘‘high’’
NT-proBNP and cTnT groups compared to the ‘‘low’’ NT-
proBNP and cTnT groups, respectively, but there was no
significant difference in the proportion of patients with DM
or hypertension between the ‘‘high’’ and ‘‘low’’ hsCRP groups.
Moreover, the proportions of patients with CAD or PAD were
significantly higher in the ‘‘high’’ cTnT group. The CCI was
significantly higher and serum albumin levels were signifi-
cantly lower in the ‘‘high’’ NT-proBNP, cTnT, and hsCRP
groups compared to their corresponding ‘‘low’’ groups. LVH
on ECG was also significantly more prevalent in all 3 ‘‘high’’
groups. Whereas all ‘‘high’’ biomarker groups had significantly
higher mean values of LAD, LVMI was significantly higher and
LVEF was significantly lower only in the ‘‘high’’ NT-proBNP
and cTnT groups, but not in the ‘‘high’’ hsCRP group. More-
over, RVSP was significantly higher in patients with ‘‘high’’
NT-proBNP compared to the ‘‘low’’ NT-proBNP (36.2 vs
30.9mm Hg, P¼ 0.039), while there were no significant differ-
ences in RVSP between the ‘‘high’’ and ‘‘low’’ cTnT and
hsCRP groups. In contrast, WBC counts were significantly
higher in the ‘‘high’’ hsCRP group compared to the ‘‘low’’
hsCRP group (Table 1).
Next, we compared CV and all-cause mortality between
the ‘‘high’’ and ‘‘low’’ biomarker groups. Even though there
were significant differences in all-cause mortality between all 3
‘‘high’’ and ‘‘low’’ biomarker groups (NT-proBNP, 11.1% vs
3.7%, P¼ 0.007; cTnT, 10.0% vs 4.9%, P¼ 0.045; and hsCRP,
9.7% vs 5.1%, P¼ 0.019), CV mortality was significantly
higher only in the ‘‘high’’ NT-proBNP (5.8% vs 0.7%,
P¼ 0.003) and cTnT groups (4.9% vs 1.6%, P¼ 0.027), but
not in the ‘‘high’’ hsCRP group (4.4% vs 2.1%, P¼ 0.198)
(Table 2). In additional analysis, we determined the cut-off
point for cTnT value based on the ROC curve, and it was
revealed to be 0.045 ng/mL, which is similar to the median level
of 0.05 ng/mL.When we divided the patients into 2 groups (high
vs low group) according to the cut-off value for cTnT and
compared all-cause and CV mortality rates, both of them were
significantly higher in the ‘‘high’’ cTnT group compared with
the ‘‘low’’ cTnT group (all-cause mortality, 12.0 vs 1.8%,
P¼ 0.001; CV mortality; 5.7 vs 0.2%, P¼ 0.004) (Supple-
mentary Table 1, http://links.lww.com/MD/A92).
Clinical Outcomes Based on Biomarker Levels
During amean follow-up duration of 17.9 8.8months, 64
patients (7.4%) died. Among them, 28 patients (48.3%) died
from CV causes. As shown in Figure 1, the CV survival rates
were significantly lower in the ‘‘high’’ NT-proBNP (P¼ 0.005)
and cTnT groups (P¼ 0.045) compared to the corresponding
‘‘low’’ groups, while there was no significant difference in CV
survival rates between the ‘‘high’’ and ‘‘low’’ hsCRP groups
(P¼ 0.115). However, the all-cause mortality rates were sig-
nificantly higher in all 3 ‘‘high’’ groups (NT-proBNP,
P¼ 0.016; cTnT, P¼ 0.040; and hsCRP, P¼ 0.007).
Time-dependent ROC curves over the entire follow-up
period are presented in Figure 2. iAUC values for CV mortality
were 0.815 (95% CI, 0.701–0.937) for traditional risk factors
(including age, gender, hypertension, and DM), and 0.897 (95%
CI, 0.794–0.984) for traditional risk factors with Ln NT-
proBNP. The estimated difference (ESD) in iAUC was 0.083
Role of NT-proBNP in Incident HD Patients(95% CI, 0.015–0.171), indicating that NT-proBNP was an
additional significant prognostic factor for CV mortality. In
addition, iAUC values for all-cause mortality were 0.748 (95%
www.md-journal.com | 3
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FIGURE 1. Kaplan–Meier survival curves for cardiovascular and all-causemortality based on themedian baseline values of NT-proBNP (A/
D), cTnT (B/E), and hsCRP (C/F). The CV survival rates were significantly lower in the ‘‘high’’ NT-proBNP and cTnT groups compared to the
corresponding ‘‘low’’ groups, while there was no significant difference in CV survival rates between the ‘‘high’’ and ‘‘low’’ hsCRP groups
(A, B, and C). However, the all-cause mortality rates were significantly higher in all 3 ‘‘high’’ groups (D, E, and F). cTnT¼cardiac troponin
T, CV¼ cardiovascular, hsCRP¼high-sensitivity C-reactive protein, NT-proBNP¼N-terminal proB-type natriuretic peptide.
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FIGURE 2. Time-dependent ROC curve analyses for cardiovascular (A) and all-causemortality (B). iAUC values for CVmortality were 0.815
(95% CI, 0.701–0.937) for traditional risk factors, and 0.897 (95% CI, 0.794–0.984) for traditional risk factors with Ln NT-proBNP. The
ESD in iAUC was 0.083 (95% CI, 0.015–0.171). In addition, iAUC values for all-cause mortality were 0.748 (95% CI, 0.655–0.828) for
traditional risk factors, and 0.778 (95% CI, 0.684–0.862) for traditional risk factors with Ln NT-proBNP, and the ESD in iAUC value for all-
cause mortality was 0.031 (95% CI, 0.001–0.088). Regarding cTnT, the ESDs in iAUC for CV and all-cause mortality were 0.054 (95% CI,
0.008–0.113) and 0.026 (95% CI, 0.001–0.079), respectively. However, the ESDs of hsCRP for CV and all-cause mortality were 0.017
(95%CI,0.003 to 0.077) and 0.006 (95%CI,0.003 to 0.034), respectively. Null model; including traditional risk factors, such as age,
gender, hypertension, and DM.

Model 1; Null model plus Ln NT-proBNP.

Model 2; Null model plus Ln cTnT.

Model 3; Null model
plus Ln hsCRP. CI¼ confidence interval, cTnT¼cardiac troponin T, CV¼ cardiovascular, hsCRP¼high-sensitivity C-reactive protein,
iAUC¼ integrated area under curve, NT-proBNP¼N-terminal proB-type natriuretic peptide, ROC¼ receiver operating curve.
Oh et al Medicine  Volume 93, Number 27, December 2014
6 | www.md-journal.com # 2014 Lippincott Williams & Wilkins
TABLE 3. Univariate Cox Proportional Regression Analysis for Cardiovascular and All-Cause Mortality
Cardiovascular Mortality All-Cause Mortality
HR (95% CI) P-Value HR (95% CI) P-Value
Age (year) 1.045 (1.012–1.078) 0.006 1.061 (1.038–1.084) <0.001
Male (vs female) 1.087 (0.505–2.338) 0.831 1.024 (0.622–1.685) 0.926
Hypertension 1.073 (0.954–1.178) 0.217 1.095 (1.020–1.165) 0.014
DM 3.347 (1.267–8.841) 0.015 1.675 (0.987–2.842) 0.056
CCI 1.112 (0.887–1.231) 0.091 1.097 (0.795–1.301) 0.105
MAP (mmHg) 1.007 (0.981–1.032) 0.613 0.994 (0.977–1.011) 0.497
Urine output (mL/day) 0.999 (0.999–1.000) 0.234 1.000 (0.999–1.000) 0.195
Hb (g/dL) 0.933 (0.744–1.168) 0.544 1.011 (0.873–1.170) 0.889
Serum albumin (g/dL) 0.852 (0.468–1.552) 0.601 0.767 (0.521–1.129) 0.179
Total cholesterol (mg/dL) 0.998 (0.989–1.006) 0.617 0.997 (0.991–1.003) 0.348
Ln NT-proBNP 2.228 (1.345–3.692) 0.002 1.392 (1.077–1.799) 0.012
Ln cTnT 1.274 (1.015–1.667) 0.015 1.182 (1.048–1.431) 0.034
Ln hsCRP 1.001 (0.839–1.194) 0.992 1.098 (0.979–1.232) 0.110
LAD (cm) 1.172 (0.611–2.246) 0.633 1.146 (0.765–1.717) 0.509
LVMI (g/m2) 1.009 (1.004–1.014) <0.001 1.005 (1.001–1.009) 0.008
LVEF (%) 0.941 (0.910–0.972) <0.001 0.977 (0.953–1.002) 0.071
CCI¼Charlson comorbidity index, CI¼ confidence interval, cTnT¼ cardiac troponin T, DM¼ diabetes mellitus, Hb¼ hemoglobin, HR¼ hazard ratio,
VE
tic
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0.684–0.862) for traditional risk factors with Ln NT-proBNP,
and the ESD in iAUC value for all-cause mortality was 0.031
(95% CI, 0.001–0.088), suggesting that NT-proBNP was also
an additional significant prognostic factor for all-cause
mortality. Regarding cTnT, the ESDs in iAUC for CV and
all-cause mortality were 0.054 (95% CI, 0.008–0.113) and
0.026 (95% CI, 0.001–0.079), respectively, which represented
that cTnT was also an additional significant useful prognostic
factor for CV and all-cause mortality. However, the ESDs of
hsCRP for CV and all-cause mortality were 0.017 (95% CI,
0.003 to 0.077) and 0.006 (95% CI, 0.003 to 0.034), respec-
tively.
hsCRP¼ high-sensitivity C-reactive protein, LAD¼ left atrial dimension, L
MAP¼mean arterial pressure, NT-proBNP¼N-terminal proB-type natriureBiomarkers as Predictors of Mortality
Univariate Cox proportional hazard regression analysis
revealed that Ln NT-proBNP and Ln cTnT but not Ln hsCRP
TABLE 4. Multivariate Cox Proportional Regression Analysis for C
Null model Model 1
HR (95% CI) P-Value HR (95% CI) P-V
Age (year) 1.066 (1.007–1.129) 0.028 1.064 (1.013–1.118) 0
Male (vs female) 0.617 (0.182–2.095) 0.439 0.782 (0.213–2.872) 0
Hypertension 1.176 (1.004–1.318) 0.045 1.140 (0.953–1.293) 0
DM 2.250 (0.578–8.756) 0.242 1.869 (0.471–7.422) 0
Ln NT-proBNP – – 3.046 (1.503–6.171) 0
Ln cTnT – – –
Ln hsCRP – – –
CI¼ confidence interval, cTnT¼ cardiac troponin T, HR¼ hazard ratio, h
LVEF¼ left ventricular ejection fraction, LVMI¼ left ventricular mass index, N
Null model: including age, gender, hypertension, and DM.
Model 1: Null modelþLn NT-proBNP.
Model 2: Null modelþLn cTnT.
Model 3: Null modelþLn hsCRP.
# 2014 Lippincott Williams & Wilkinswere associated with a higher risk of CV (Ln NT-proBNP,
HR¼ 2.228, P¼ 0.002; Ln cTnT, HR¼ 1.274, P¼ 0.015) and
all-cause mortality (Ln NT-proBNP, HR¼ 1.392, P¼ 0.012; Ln
cTnT, HR¼ 1.182, P¼ 0.034). Moreover, age and LVMI were
found to be significant predictors of CV and all-cause mortality.
However, hypertension was demonstrated to be associated with
all-cause mortality but not with CV mortality, while DM and
LVEF were revealed as significant risk factors only for CV
mortality (Table 3). In multivariate regression analyses, NT-
proBNP (CV, HR¼ 2.236 [1.304–3.831], P¼ 0.003; and all-
cause, HR¼ 1.361 [1.034–1.793], P¼ 0.028) was still found as
a significant independent risk factor for CV and all-cause
mortality even after adjustment for traditional risk factors,
whereas cTnT and hsCRP were not significant prognostic
F¼ left ventricular ejection fraction, LVMI¼ left ventricular mass index,
peptide.factors (Tables 4 and 5). Furthermore, we calculated the NR
and the IDI to assess the ability of the models with biomarkers to
correctly reclassify patients compared to the model withou
ardiovascular Mortality
Model 2 Model 3
alue HR (95% CI) P-Value HR (95% CI) P-Value
.014 1.080 (1.016–1.149) 0.014 1.040 (1.003–1.079) 0.036
.711 0.605 (0.174–2.102) 0.429 1.080 (0.480–2.430) 0.852
.134 1.188 (1.016–1.330) 0.033 1.072 (0.949–1.181) 0.240
.374 2.035 (0.501–8.256) 0.320 3.805 (1.287–11.246) 0.158
.002 – – – –
– 2.009 (0.986–3.455) 0.097 – –
– – – 0.962 (0.798–1.160) 0.688
sCRP¼ high-sensitivity C-reactive protein, LAD¼ left atrial dimension
T-proBNP¼N-terminal proB-type natriuretic peptide.
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TABLE 5. Multivariate Cox Proportional Regression Analysis for All-Cause Mortality
Null Model Model 1 Model 2 Model 3
HR (95% CI) P-Value HR (95% CI) P-Value HR (95% CI) P-Value HR (95% CI) P-Value
Age (year) 1.061 (1.024–1.100) 0.001 1.060 (1.024–1.098) 0.001 1.065 (1.027–1.105) 0.001 1.060 (1.034–1.087) <0.001
Male (vs. female) 0.920 (0.430–1.969) 0.830 0.922 (0.427–1.987) 0.835 0.944 (0.438–2.038) 0.884 0.888 (0.515–1.531) 0.668
Hypertension 1.115 (1.007–1.212) 0.038 1.098 (0.986–1.197) 0.085 1.114 (1.006–1.210) 0.039 1.079 (0.999–1.152) 0.053
DM 1.533 (0.671–3.503) 0.311 1.551 (0.679–3.545) 0.298 1.391 (0.599–3.230) 0.442 1.592 (0.898–2.823) 0.111
Ln NT-proBNP – – 1.458 (1.061–2.005) 0.020 – – – –
Ln cTnT – – – – 1.509 (0.891–2.136) 0.201 – –
Ln hsCRP – – – – – – 0.999 (0.884–1.129) 0.989
CI¼ confidence interval, cTnT¼ cardiac troponin T, HR¼ hazard ratio, hsCRP¼ high-sensitivity C-reactive protein, LAD¼ left atrial dimension,
LVEF¼ left ventricular ejection fraction, LVMI¼ left ventricular mass index, NT-proBNP¼N-terminal proB-type natriuretic peptide.
Null model: including age, gender, hypertension, and DM.
Oh et al Medicine  Volume 93, Number 27, December 2014biomarkers (model including traditional risk factors and each
cardiac biomarker). The prognostic powers for null and each
cardiac biomarker model are shown in Table 6. There were
significant differences between null model (including traditional
risk factors) and null model plus NT-proBNP or cTnT, but not
hsCRP. However, NT-proBNPwas amore prognosticmarker for
CV and all-cause mortality compared to cTnT.
DISCUSSION
Even though a number of previous studies have found that
some biochemical markers, such as NT-proBNP, cTnT, and
hsCRP, predict CV mortality in ESRD patients, most of the
patients included in these studies were prevalent dialysis
patients.10,11,23 The results of the present study demonstrate
that NT-proBNP concentration, but neither cTnT nor hsCRP, is
independently associated with CV and all-cause mortality and is
a more prognostic marker for CV and all-cause mortality
compared to cTnT. To our knowledge, the present study is
the first study to investigate and to compare the impact of
various biomarkers at the time of dialysis initiation on CV and
all-cause mortality in a large, ethnically homogeneous, incident
HD patient cohort.
Model 1: Null modelþLn NT-proBNP.
Model 2: Null modelþLn cTnT.
Model 3: Null modelþLn hsCRP.Cardiac biomarkers, including BNP, NT-proBNP, cTnT,
and cTnI, have been considered to represent the current status
and function of the heart.15–21 In addition, a number of previous
TABLE 6. Prognostic Power for Cardiovascular and All-Cause Mo
and IDI
Cardiovascular Mortality
NRI (95% CI) P-Value IDI (95% CI) P-V
Null model – – – –
Model 1 0.410 (0.045 to 0.775) 0.028 0.150 (0.058 to 0.242) 0.0
Model 2 0.083 (0.000 to 0.246) 0.037 0.029 (0.001 to 0.066) 0.0
Model 3 0.003 (0.002 to 0.009) 0.317 0.004 (0.014 to 0.006) 0.4
CI¼ confidence interval, IDI¼ integrated discrimination improvement, N
Null model; age, gender, hypertension, and DM.
Model 1: Null modelþLn NT-proBNP.
Model 2: Null modelþLn cTnT.
Model 3: Null modelþLn hsCRP.
8 | www.md-journal.comstudies have shown that these cardiac biomarkers are useful in
defining CV risk stratification in the general population and
in patients with specific diseases.8,10,11,22,23 Moreover, the
biology, pathophysiology, and the prognostic value of these
biomarkers in ESRD patients have already been extensively
reviewed by Angela and Lai.8 In accordance with most previous
studies on prevalent ESRD patients, we also found that
NT-proBNP was an independent risk factor for CV and all-
cause mortality in incident HD patients. Moreover, the prog-
nostic value of NT-proBNP for CV and all-cause mortality was
somewhat higher than that of cTnT, which was in concordance
with the study by Satyan et al.10 The reason for this better
predictive power of NT-proBNP has not been fully explained,
but one possibility is that NT-proBNP is more closely associ-
ated with LVH, which is known to have a great impact on CV
and all-cause mortality in ESRD patients.10,18,19,23
LVH is a well-known powerful independent predictor of
CVmortality in patients with ESRD.35–38Moreover, the change
in LVH has been demonstrated as a strong prognostic factor in
these patients.36,37 A previous prospective study on prevalent
HD patients revealed that the rates of LVMI increase were
significantly higher in patients with incident CV events than in
those without such events and that cardiovascular event-free
survival in patients with changes in LVMI below the 25th
percentile was significantly higher than in those with changes
above the 75th percentile.36,39 Similarly, in a cohort study of
rtality for Null and Each Cardiac Biomarker Models Using NRI
All-Cause Mortality
alue NRI (95% CI) P-Value IDI (95% CI) P-Value
– – – –
01 0.130 (0.002 to 0.302) 0.024 0.048 (0.015 to 0.081) 0.006
31 0.097 (0.002 to 0.219) 0.036 0.026 (0.001 to 0.051) 0.041
28 0.001 (0.001 to 0.002) 0.926 0.002 (0.002 to 0.006) 0.356
RI¼ net reclassification index.
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153 incident ESRD patients receiving HD, a 10% reduction in
LVMduring amean follow-up duration of 54 months resulted in
a 28% decrease in CVmortality and a 22% decrease in all-cause
mortality.37,39 In that study, LVM regression was also inde-
pendently associated with improved patient survival even after
adjustment for age, gender, diabetes, history of CVD, and all
nonspecific CV risk factors.37 While these 2 studies used
echocardiography to assess LVMI or LVM as an indicator of
LVH, similar results were observed in hypertensive patients
with LVH on ECG.40,41 In the current study, the differences in
the proportion of patients with LVH on ECG and LVMI values
were most prominent between ‘‘high’’ and ‘‘low’’ NT-proBNP
groups. Furthermore, NT-proBNP but neither cTnT nor hsCRP
significantly correlated with LVMI. In addition, most previous
studies used LVMI, assessed by echocardiography, as an
indicator of LVH. Meanwhile, since NT-proBNP synthesis
and secretion are mainly related to increased LV wall stress,
circulating NT-proBNP levels are considered to reflect the
degree of LV overload. Taken together, we surmised that the
best prognostic value of NT-proBNP was attributed to its strong
association with LVH.
In this study, the median levels of cTnT (0.05 ng/mL) were
only one-half of the reference cTnT concentrations (0.1 ng/mL)
used in most previous studies,12,42,43 while the median
NT-proBNP levels were comparable to other studies.10,11,23
In addition, even though the mean NT-proBNP concentrations
were significantly lower in the ‘‘low’’ cTnT group compared to
the ‘‘high’’ cTnT group (9524 vs 20,927 pg/mL, P< 0.001), the
mean NT-proBNP levels in the ‘‘low’’ cTnT group were
regarded as significant concentrations in previous stu-
dies.10,11,23 These findings may in part contribute to the lower
predictive power of cTnT for mortality than NT-proBNP.
Moreover, the proportion of patients with preexisting CAD
and PAD was significantly higher in the ‘‘high’’ cTnT group
compared to the ‘‘low’’ cTnT group. In the future, clarification
is needed to determine whether a weaker association between
cTnT and mortality can be attributed to more meticulous care
and more intensive treatment received by these patients.
hsCRP, an acute phase reactant, has been considered a
marker of inflammation.24–26 Since accumulating evidence
indicates that inflammation is an integral part of the develop-
ment and progression of atherosclerosis, it has been proposed
that hsCRP levels are closely linked with the presence of
CVD.24–26 Furthermore, numerous studies have found that
the serum concentration of hsCRP is predictive of CV mortality
as well as future CV events in the general population.26
However, the results of previous studies on the association
between hsCRP levels and CVD or CV mortality in ESRD
patients are not consistent.11,23 These conflicting results may be
due to prevalent chronic low-grade inflammation in ESRD
patients.44 Especially in HD patients, extracorporeal circulation
of blood, bioincompatible dialyzer, and non-sterile dialysate
and back leak of dialysate may lead to a state of chronic
inflammation.45–47 In addition, hsCRP levels can be elevated
by diabetes, insulin resistance, and dyslipidemia, all of which
are frequently observed in ESRD patients on HD.14,18 More-
over, hsCRP concentrations are reported to vary widely, both
intra- and interindividually.48,49 Therefore, the prognostic
power of hsCRP for CV mortality could be lessened in ESRD
patients. The results of the present study, demonstrating the lack
of an association of hsCRP with CVmortality can be interpreted
Medicine  Volume 93, Number 27, December 2014in this point of view. Meanwhile, we showed that the all-cause
mortality was significantly more prevalent in the ‘‘high’’
hsCRP group compared to the ‘‘low’’ hsCRP group. The
# 2014 Lippincott Williams & WilkinsKaplan–Meier plot also revealed that all-cause mortality rates
were significantly higher in the ‘‘high’’ hsCRP group. Since
WBC counts and serum ferritin levels were significantly higher
in the ‘‘high’’ hsCRP group compared to the ‘‘low’’ hsCRP
group, we inferred that infection-related death may account for
this higher all-cause mortality in the ‘‘high’’ hsCRP group. Due
to a relatively small number of deaths from infection, however,
it was difficult to analyze the association between hsCRP and
infection-related mortality. By the same token, the independent
predictability of hsCRP for all-cause mortality might not
be significant.
There are several limitations of this study. First, since the
study subjects were all Korean incident HD patients, the
associations between various biomarkers and mortality may
not be generalizable to other populations. Second, all biomarker
measurements and echocardiography were performed only once
during the admission for HD commencement; therefore, it was
difficult to clarify why some but not all biomarkers had
associations with mortality and to demonstrate the impact of
the changes in these biomarkers on patients’ clinical outcomes.
Future studies will be necessary to find out whether the changes
in biomarkers over time have an association with the clinical
outcomes. Third, CV and all-cause mortality rates in the current
study were lower compared to those in previous studies on
Western ESRD patients.10,11,23 We hypothesize that the differ-
ence was mainly attributed to disparate ethnicities, because the
mortality rates of our patients were comparable to those of
Japanese patients on HD.50 Fourth, we arbitrarily stratified the
patients based on the median values of cardiac and inflamma-
tory biomarkers. Previous studies, which investigated the
impact of biomarkers on CV outcomes in ESRD patients, also
used very diverse cut-off values for these biomarkers.10,11,22,23
Therefore, it is necessary to define the best cut-off concen-
trations of each biomarker in both HD and peritoneal dialysis
patients. In additional analyses, the clinical outcomes were
compared after stratifying these patients into tertiles (lower,
middle, and upper groups) according to the baseline NT-
proBNP, cTnT, and hsCRP concentrations. During the fol-
low-up period, patients in the upper tertile of NT-proBNP
and cTnT exhibited significantly higher CV and all-cause
mortality rates compared to those in other tertiles (P¼ 0.011
and P¼ 0.005 for NT-proBNP, and P¼ 0.046 and P¼ 0.041 for
cTnT). On the contrary, only all-cause mortality rates in the
upper tertile of hsCRP were significantly higher than those in
other tertiles (P¼ 0.017), while there was just a trend for an
increase in CVmortality in patients in the upper tertile of hsCRP
(P¼ 0.292). Meanwhile, Shafi et al10 also suggested that a
stratification approach based on cTnI and NT-proBNP levels
could be useful to control blood pressure properly in hemodia-
lysis patients. Taken together, not only cTnT but also cTnI may
be associated with worse clinical outcomes in incident HD
patients. Fifth, the follow-up duration was short in this study.
Even though the follow-up duration seems to be relatively short,
these patients have continuously been followed up and thus a
better long-term study will be carried out in a near future.
Moreover, there were not a few follow-up losses, which could
lessen the statistical power, but it was not easy to find out the
exact reasons for them. Therefore, the results of this study
should be interpreted with caution. We also regarded this
situation as one of the limitations of the present study. Sixth,
during the follow-up duration, all-cause mortality occurred in
Role of NT-proBNP in Incident HD Patients64 patients, whereas only 28 patients died of CV events. Even
though the number of variables in a null model might be suitable
for analyzing all-cause mortality, we surmised that the risk of
www.md-journal.com | 9
overfitting could be run when all the variables in a null model
was applied for investigating CV mortality. Therefore, a further
study with a long-term follow-up duration is needed to verify
our results. Seventh, the measurement of biomarkers was not
made with immediate post-dialysis blood samples when clinical
euvolemia was reached. Considering the results of some
previous studies showing that post-dialysis hormone levels
may vary significantly,51 there is a possibility that the levels
of biomarkers can be influenced by patients’ hydration status.
Therefore, if more than one measurement in separate dialysis
session was performed, the results might be even more accurate.
Furthermore, the current study did not perform an objective
fluid balance monitoring, such as inferior vena cava diameter,
bioimpedance, and continuous blood volume measurements. In
this cohort study, however, routine chest X-rays and physical
examination were performed to evaluate the volume status of
these patients, and these cardiac biomarkers were determined
close to time of discharge, when the physicians considered their
patients to be clinically euvolemic. Since all laboratory data
including NT-proBNP were compared to each other in this
study, we presumed that measurements of these laboratory
parameters on different days might be regarded rather as a
more serious issue. In addition, target dry weights were estab-
lished for each patient totally based on their physicians’ judg-
ment. Therefore, we could not completely discriminate among
hypovolemic, euvolemic, and hypervolemic patients after dialy-
sis. However, since the laboratory measurements and echocar-
diography were performed close to the time of discharge, we
inferred that a majority of patients were euvolemic at post-
dialysis. Despite these limitations, to our knowledge, the present
study is the first study to investigate and to compare the
association of NT-proBNP, cTnT, and hsCRP levels at the time
of dialysis initiation with CV and all-cause mortality in a large,
ethnically homogeneous, incident HD patient cohort. Further
studies are needed to clarify whether the concentrations of these
biomarkers can provide a guideline for treating ESRD patients
and whether serial monitoring rather than a single measurement
of biomarkers is helpful in identifying ESRD patients at a high
risk of CV mortality.
In conclusion, NT-proBNP is the biomarker that results in
the most added prognostic value on top of traditional risk factors
for CV and all-cause mortality in incident HD patients.
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